These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36501086)

  • 1. Effect of Ferric Carboxymaltose Supplementation in Patients with Heart Failure with Preserved Ejection Fraction: Role of Attenuated Oxidative Stress and Improved Endothelial Function.
    Mollace A; Macrì R; Mollace R; Tavernese A; Gliozzi M; Musolino V; Carresi C; Maiuolo J; Nicita M; Caminiti R; Paone S; Barillà F; Volterrani M; Mollace V
    Nutrients; 2022 Nov; 14(23):. PubMed ID: 36501086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Anker SD; Ponikowski P; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Metra M; Piña IL; Coats AJS; Rosano G; Dorigotti F; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Butler J
    Eur J Heart Fail; 2022 May; 24(5):833-842. PubMed ID: 35334136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.
    López-Vilella R; Lozano-Edo S; Arenas Martín P; Jover-Pastor P; Ezzitouny M; Sorolla Romero J; Calvo Asensio M; Martínez-Solé J; Guerrero Cervera B; Sánchez Martínez JC; Donoso Trenado V; Sánchez-Lázaro I; Martinez Dolz L; Almenar Bonet L
    ESC Heart Fail; 2022 Feb; 9(1):133-145. PubMed ID: 34964300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.
    Drozd MD; Tkaczyszyn M; Kasztura M; Węgrzynowska-Teodorczyk K; Flinta I; Banasiak W; Ponikowski P; Jankowska EA
    Cardiol J; 2024; 31(2):300-308. PubMed ID: 37853824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
    Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
    Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
    Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
    Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
    Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
    Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
    Yeo TJ; Yeo PSD; Hadi FA; Cushway T; Lee KY; Yin FF; Ching A; Li R; Loh SY; Lim SL; Wong RC; Tai BC; Richards AM; Lam CSP
    ESC Heart Fail; 2018 Apr; 5(2):344-353. PubMed ID: 29345426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial.
    Santas E; Del Canto I; Cardells I; Miñana G; Llàcer P; Almenar L; Fácila L; Maceira AM; Sanchis J; Núñez J;
    ESC Heart Fail; 2024 Apr; 11(2):1258-1262. PubMed ID: 38115745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE-HF trial.
    Bakogiannis C; Mouselimis D; Tsarouchas A; Papadopoulos CE; Theofillogiannakos EK; Lechat E; Antoniadis AP; Pagourelias ED; Kelemanis I; Tzikas S; Fragakis N; Efthimiadis GK; Karamitsos TD; Doumas M; Vassilikos VP
    ESC Heart Fail; 2023 Apr; 10(2):1184-1192. PubMed ID: 36647691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
    Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
    Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.
    Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh TA; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD
    ESC Heart Fail; 2014 Sep; 1(1):52-58. PubMed ID: 28834668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
    Ponikowski P; Mentz RJ; Hernandez AF; Butler J; Khan MS; van Veldhuisen DJ; Roubert B; Blackman N; Friede T; Jankowska EA; Anker SD
    Eur Heart J; 2023 Dec; 44(48):5077-5091. PubMed ID: 37632415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
    Butler J; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Dorigotti F; Metra M; Piña IL; Coats AJS; Rosano G; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Anker SD; Ponikowski P
    Eur J Heart Fail; 2022 May; 24(5):821-832. PubMed ID: 35279929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life.
    Bekfani T; Pellicori P; Morris D; Ebner N; Valentova M; Sandek A; Doehner W; Cleland JG; Lainscak M; Schulze PC; Anker SD; von Haehling S
    Clin Res Cardiol; 2019 Feb; 108(2):203-211. PubMed ID: 30051186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure.
    Caravita S; Faini A; Vignati C; Pelucchi S; Salvioni E; Cattadori G; Baratto C; Torlasco C; Contini M; Villani A; Malfatto G; Perger E; Lombardi C; Piperno A; Agostoni P; Parati G
    Eur J Heart Fail; 2022 Oct; 24(10):1940-1949. PubMed ID: 35867685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.
    Martens P; Dupont M; Dauw J; Nijst P; Herbots L; Dendale P; Vandervoort P; Bruckers L; Tang WHW; Mullens W
    Eur Heart J; 2021 Dec; 42(48):4905-4914. PubMed ID: 34185066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IV Sodium Ferric Gluconate Complex in Patients Hospitalized Due to Acute Decompensated Heart Failure and Iron Deficiency.
    Borreda I; Zukermann R; Epstein D; Marcusohn E
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484211055639. PubMed ID: 34994220
    [No Abstract]   [Full Text] [Related]  

  • 20. Markers of Iron Metabolism and Outcomes in Patients with Heart Failure: A Systematic Review.
    Dhaliwal S; Kalogeropoulos AP
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.